Clinical Trials on Melanoma in Situ

Total 68608 results

MelanomaPRO, Russia

Recruiting

Clinical Outcomes and Biomarkers in Patients With Stage 0-IV Melanoma in Real Clinical Practice (ISABELLA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma, Stage II | Melanoma, Uveal | Melanoma in Situ | Melanoma, Ocular

Russian Federation
Peking University

Unknown

Research of Pathological Imaging Diagnosis of Ocular Tumors Based on New Artificial Intelligence Algorithm

Melanoma (Skin) | Basal Cell Carcinoma | Squamous Cell Carcinoma in Situ | Ocular Tumor | Melanoma in Situ | Nevus Eye | Sebaceous Gland Carcinoma of the Eyelid
Carman Giacomantonio
Nova Scotia Health Authority

Terminated

Pre-Treatment of Highly Suspicious Pigmented Skin Lesions With Interleukin-2 (IL-2)

Melanoma (Skin) | Melanoma in Situ

Canada
University of Texas Southwestern Medical Center

Completed

SAbR Induced Innate Immunity in Urothelial Carcinoma, Melanoma, and Cervical Carcinoma

Melanoma | Urothelial Carcinoma | Cervical Carcinoma in Situ

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Autologous CD8+ SLC45A2-Specific T Lymphocytes With Cyclophosphamide, Aldesleukin, and Ipilimumab in Treating Patients With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma | Metastatic Malignant Neoplasm in the Liver

United States
Mayo Clinic

Not yet recruiting

Aerosolized Sargramostim Added to Immunotherapy for the Treatment of Patients With Metastatic Melanoma to the Lung

Metastatic Melanoma | Recurrent Melanoma | Unresectable Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Lung

United States
Kari Kendra

Recruiting

Natural Killer Cell Therapy (UD TGFbetai NK Cells) and Temozolomide for the Treatment of Stage IV Melanoma Metastatic to the Brain

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
Centre Hospitalier Universitaire Vaudois

Active, not recruiting

Analysis of the Modulation of the Tumor Microenvironment by MK-3475 (Pembrolizumab) Using a Systems Biology Approach (PEMSYS)

Metastatic Melanoma Naive to Immune Therapy in Metastatic Setting

Switzerland
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the Brain

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Nivolumab With Trametinib and Dabrafenib, or Encorafenib and Binimetinib in Treating Patients With BRAF Mutated Metastatic or Unresectable Stage III-IV Melanoma

Metastatic Melanoma | Stage III Cutaneous Melanoma AJCC v7 | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable Melanoma | Metastatic Malignant Neoplasm in the Brain | Stage IIIA Cutaneous Melanoma AJCC v7 | Stage IIIB Cutaneous Melanoma AJCC v7

United States
University of Miami
University of Miami Sylvester Comprehensive Cancer Center

Withdrawn

Mohs and Immunofluorescence for Malignant Melanoma In Situ

Lentigo Maligna | Melanoma In Situ

United States
Thomas Jefferson University

Recruiting

Transarterial Chemoembolization for the Treatment of Uveal Melanoma With Liver Metastases

Metastatic Uveal Melanoma | Metastatic Malignant Neoplasm in the Liver | Stage IV Choroidal and Ciliary Body Melanoma AJCC V8

United States
Sidney Kimmel Cancer Center at Thomas Jefferson...
Bristol-Myers Squibb

Active, not recruiting

Ipilimumab and Nivolumab With Immunoembolization in Treating Participants With Metastatic Uveal Melanoma in the Liver

Metastatic Uveal Melanoma | Metastatic Malignant Neoplasm in the Liver | Stage IV Uveal Melanoma AJCC v7

United States
Leiden University Medical Center
Pierre Fabre Laboratories

Recruiting

(Neo)Adjuvant BRAF/MEK Inhibition in pN1c Melanoma

Melanoma Stage III | In-Transit Metastasis of Cutaneous Melanoma

Netherlands
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Encorafenib and Binimetinib Before Surgery for Melanoma With Lymph Node Involvement

Melanoma of Unknown Primary | Pathologic Stage IIIB Cutaneous Melanoma AJCC v8 | Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 | Pathologic Stage IIID Cutaneous Melanoma AJCC v8 | Recurrent Cutaneous Melanoma | Metastatic Malignant Neoplasm in Lymph Node

United States
Mayo Clinic
National Cancer Institute (NCI)

Recruiting

E6201 and Dabrafenib for the Treatment of Central Nervous System Metastases From BRAF V600 Mutated Metastatic Melanoma

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Central Nervous System

United States
Sidney Kimmel Comprehensive Cancer Center at Johns...
Accuray Incorporated

Completed

SRS and Nivolumab in Treating Patients With Newly Diagnosed Melanoma Metastases in the Brain or Spine

Stage IV Skin Melanoma | Metastatic Malignant Neoplasm in the Brain | Metastatic Malignant Neoplasm in the Spine

United States
TriSalus Life Sciences, Inc.

Active, not recruiting

Intrahepatic Delivery of SD-101 by Pressure-Enabled Regional Immuno-oncology (PERIO), With Checkpoint Blockade in Adults With Metastatic Uveal Melanoma

Metastatic Uveal Melanoma in the Liver

United States
Melanoma Institute Australia

Withdrawn

Intralesional Sclerosant for in Transit and Cutaneous Melanoma Metastases (INTRANS)

Melanoma | In-Transit Metastasis of Cutaneous Melanoma

Australia
University Hospital Tuebingen

Completed

NAM-Trial: Multiferon in Malignant Melanoma

Locoregional Metastases in Malignant Melanoma Stages IIIB/C

Germany
Emory University
National Cancer Institute (NCI); NovoCure Ltd.

Recruiting

Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-100M for the Treatment of Melanoma Brain Metastases

Metastatic Melanoma | Melanoma of Unknown Primary | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma | Metastatic Ocular Melanoma

United States
Dana-Farber Cancer Institute
Novartis

Completed

Imatinib in Patients With Mucosal or Acral/Lentiginous Melanoma (BUS255)

Mucosal Melanoma | Acral/Lentiginous Melanoma | Chronically Sun Damaged Melanomas

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Recruiting

A Study to Compare the Administration of Encorafenib + Binimetinib + Nivolumab Versus Ipilimumab + Nivolumab in BRAF-V600 Mutant Melanoma With Brain Metastases

Metastatic Melanoma | Metastatic Cutaneous Melanoma | Acral Lentiginous Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Metastatic Mucosal Melanoma

United States
Perspective Therapeutics

Recruiting

MC1R-targeted Alpha-particle Therapy Trial in Adults With Advanced Melanoma

Metastatic Melanoma | Melanoma (Skin) | Mucosal Melanoma | Melanoma Stage IV | Melanoma Stage III | Melanoma, Uveal

United States
Fudan University

Not yet recruiting

PD-1 Inhibitors With or Without Radiation in Advanced Melanoma

the Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced Melanoma

China
Sidney Kimmel Comprehensive Cancer Center at Johns...

Terminated

SRS (Stereotactic Radiosurgery) Plus Ipilimumab

Newly Diagnosed Melanoma Metastases in the Brain and Spine

United States
Gustave Roussy, Cancer Campus, Grand Paris

Completed

Trial of Ipilimumab After Isolated Limb Perfusion, in Patients With Metastases Melanoma (ILP+/-IPI)

In-transit Metastases Melanoma Stage IIIB and IIIC

France
UNC Lineberger Comprehensive Cancer Center
Amgen

Completed

Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma

Melanoma | Melanoma (Skin) | Melanoma Stage Iv | Melanoma Stage Iii | Cutaneous Melanoma

United States
H. Lee Moffitt Cancer Center and Research Institute
Turnstone Biologics, Corp.

Recruiting

Proof of Concept of TBio-4101, Lymphodepleting Chemo, IL-2 for Relapsed/Refractory Melanoma

Metastatic Melanoma | Conjunctival Melanoma | Ocular Melanoma | Unresectable Melanoma | Uveal Melanoma | Cutaneous Melanoma | Mucosal Melanoma | Iris Melanoma | Acral Melanoma | Non-Cutaneous Melanoma

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain | Refractory Melanoma | BRAF V600 Wild Type | Intracranial Melanoma

United States
National Cancer Institute (NCI)

Completed

Phase II Study of Short-Term Cultured Anti-Tumor Autologous Lymphocytes After Lymphocyte-Depleting Chemotherapy in Metastatic Melanoma

Melanoma | Malignant Melanoma | Melanoma, Experimental | Experimental Melanomas

United States
Alliance for Clinical Trials in Oncology

Withdrawn

Testing the Safety and Effectiveness of Combining Two Drugs, PLX2853 and Trametinib in the Treatment of Advanced Uveal Melanoma

Metastatic Uveal Melanoma | Advanced Uveal Melanoma | Unresectable Uveal Melanoma
Vanderbilt-Ingram Cancer Center

Recruiting

Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors

Metastatic Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Refractory Melanoma

United States
National Cancer Institute (NCI)

Completed

Carboplatin and Paclitaxel With or Without Sorafenib Tosylate in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed by Surgery

Stage IV Skin Melanoma | Recurrent Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Mucosal Melanoma | Stage IIIA Skin Melanoma

United States, Australia
Roswell Park Cancer Institute

Completed

Intravital Microscopy in Identifying Tumor Vessels in Patients With Stage IB-IIIC Melanoma Undergoing Sentinel Lymph Node Biopsy

Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma | Stage IB Skin Melanoma

United States
Novartis Pharmaceuticals

Terminated

A Phase I/Ib Study of NIZ985 Alone and in Combination With Spartalizumab

In Escalation: All Patients With Solid Tumors and Lymphoma | In Expansion: Melanoma, Non-small Cell Lung Cancer

United States, Italy, Taiwan, Belgium, Spain, Germany, Japan
Emory University
Genentech, Inc.

Active, not recruiting

Rituximab and Hyaluronidase Human in Patients With Advanced Melanoma Undergoing Nivolumab and Ipilimumab Therapy

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Unresectable Melanoma | Stage III Melanoma | Stage IIIA Skin Melanoma | Cutaneous Melanoma, Stage III | Cutaneous Melanoma, Stage IV

United States
Mayo Clinic
National Cancer Institute (NCI)

Completed

MART-1 Antigen With or Without TLR4 Agonist GLA-SE in Treating Patients With Stage II-IV Melanoma That Has Been Removed by Surgery

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIA Skin Melanoma | Stage IIB Skin Melanoma | Stage IIC Skin Melanoma | Stage IIIA Skin Melanoma

United States
Viewpoint Molecular Targeting
Mayo Clinic

Completed

Targeted Imaging of Melanoma for Alpha-Particle Radiotherapy (TIMAR1)

Melanoma (Skin) | Melanoma Stage IV | Melanoma, Uveal | Melanoma, Mucosal

United States
Biocad

Recruiting

A Clinical Study of BCD-217 (Nurulimab + Prolgolimab) Followed by Anti-PD-1 Compared to Anti-PD-1 Monotherapy as First-Line Treatment in Subjects With Unresectable/Metastatic Melanoma (OCTAVA)

Melanoma | Melanoma (Skin) | Melanoma Stage IV | Melanoma Stage III | Melanoma Metastatic | Melanoma Unresectable | Melanoma Advanced

India, Russian Federation, Belarus
Delcath Systems Inc.

Active, not recruiting

An Open-Label Expanded Access Study of the Melphalan/Hepatic Delivery System (HDS) in Patients With Hepatic Dominant Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
Vanderbilt-Ingram Cancer Center
National Cancer Institute (NCI)

Terminated

Pembrolizumab in Treating Patients With Advanced Uveal Melanoma

Stage IV Uveal Melanoma | Stage IIIA Uveal Melanoma | Stage IIIB Uveal Melanoma | Stage IIIC Uveal Melanoma

United States
University of Wisconsin, Madison

Recruiting

Correlating Early FDG PET/CT and ctDNA in Immune Checkpoint Inhibitor (ICI)-Treated Melanoma Patients

Melanoma | Unresectable Melanoma | Melanoma Stage IV | Melanoma Stage III

United States
Innovent Biologics (Suzhou) Co. Ltd.
Innovent Biologics (USA), Inc.

Withdrawn

A Platform Study of Novel Immunotherapy Products in Participants With Previously Treated Unresectable or Metastatic Cutaneous Melanoma

Metastatic Cutaneous Melanoma | Unresectable Cutaneous Melanoma

United States, Germany, France, Australia, Spain, Switzerland, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases

Metastatic Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8 | Pathologic Stage IV Cutaneous Melanoma AJCC v8 | Metastatic Malignant Neoplasm in the Brain

United States
BioNTech SE
Regeneron Pharmaceuticals

Active, not recruiting

Trial With BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Anti-PD-1-refractory/Relapsed, Unresectable Stage III or IV Melanoma

Unresectable Melanoma | Melanoma Stage IV | Melanoma Stage III

United States, Spain, Germany, Italy, Australia, United Kingdom, Poland
Joanne Jeter
National Cancer Institute (NCI); Merck Ltd.

Withdrawn

Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification

Stage IV Skin Melanoma | Stage IIIB Skin Melanoma | Stage IIIC Skin Melanoma | Stage IIIA Skin Melanoma
Scancell Ltd

Recruiting

SCIB1 in Melanoma Patients Receiving Either Nivolumab With Ipilimumab or Pembrolizumab (The SCOPE Study)

Melanoma (Skin) | Malignant Melanoma | Melanoma Stage IV | Melanoma Stage III

United Kingdom
National Cancer Institute (NCI)

Terminated

Immunotherapy Using Tumor Infiltrating Lymphocytes for Patients With Metastatic Ocular Melanoma

Metastatic Uveal Melanoma | Metastatic Ocular Melanoma

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing Treatment With Ipilimumab and Nivolumab Compared to Treatment With Ipilimumab Alone in Advanced Melanoma

Unresectable Cutaneous Melanoma | Unresectable Melanoma | Clinical Stage III Cutaneous Melanoma AJCC v8 | Melanoma of Unknown Primary | Mucosal Melanoma | Clinical Stage IV Cutaneous Melanoma AJCC v8

United States

Clinical Trials on Melanoma in Situ

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in United Arab Emirates

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations